Your browser doesn't support javascript.
loading
Mostrar: 20 | 50 | 100
Resultados 1 - 1 de 1
Filtrar
Mais filtros

Base de dados
Ano de publicação
Tipo de documento
Intervalo de ano de publicação
1.
Proc Natl Acad Sci U S A ; 120(4): e2211933120, 2023 01 24.
Artigo em Inglês | MEDLINE | ID: mdl-36656866

RESUMO

Metformin is the most prescribed drug for DM2, but its site and mechanism of action are still not well established. Here, we investigated the effects of metformin on basolateral intestinal glucose uptake (BIGU), and its consequences on hepatic glucose production (HGP). In diabetic patients and mice, the primary site of metformin action was the gut, increasing BIGU, evaluated through PET-CT. In mice and CaCo2 cells, this increase in BIGU resulted from an increase in GLUT1 and GLUT2, secondary to ATF4 and AMPK. In hyperglycemia, metformin increased the lactate (reducing pH and bicarbonate in portal vein) and acetate production in the gut, modulating liver pyruvate carboxylase, MPC1/2, and FBP1, establishing a gut-liver crosstalk that reduces HGP. In normoglycemia, metformin-induced increases in BIGU is accompanied by hypoglycemia in the portal vein, generating a counter-regulatory mechanism that avoids reductions or even increases HGP. In summary, metformin increases BIGU and through gut-liver crosstalk influences HGP.


Assuntos
Trato Gastrointestinal , Glucose , Fígado , Metformina , Animais , Humanos , Camundongos , Células CACO-2 , Diabetes Mellitus Tipo 2 , Glucose/metabolismo , Hipoglicemiantes/farmacologia , Fígado/metabolismo , Metformina/farmacologia , Tomografia por Emissão de Pósitrons combinada à Tomografia Computadorizada , Trato Gastrointestinal/metabolismo
SELEÇÃO DE REFERÊNCIAS
DETALHE DA PESQUISA